Conferences - Results from #9700

ASCO 2017: Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup June 5, 2017

ASCO 2017: IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezo or sunitinib June 5, 2017

ASCO 2017: First-line avelumab + axitinib therapy in patients with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial June 5, 2017

ASCO 2017: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression June 5, 2017

ASCO 2017: Liquid Biopsies: Current Utility and Future Directions June 5, 2017

ASCO 2017: Selection, Timing, and Interpretation of Metastatic Castration-Resistant Prostate Cancer Lesions June 5, 2017

ASCO 2017: Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in patients with advanced renal cell carcinoma June 5, 2017

ASCO 2017: TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents June 5, 2017

ASCO 2017: A phase III study of atezolizumab vs placebo as adjuvant therapy in renal cell carcinoma patients at high risk of recurrence following resection (IMmotion010) June 5, 2017

ASCO 2017: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC) June 5, 2017

ASCO 2017: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC) June 5, 2017

ASCO 2017: A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC) June 5, 2017

ASCO 2017: A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC) June 5, 2017

ASCO 2017: Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101) June 5, 2017

ASCO 2017: The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer June 5, 2017

ASCO 2017: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer June 5, 2017

ASCO 2017: Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045 June 5, 2017

ASCO 2017: Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study June 5, 2017

ASCO 2017: Challenges in Translating Molecular Results Into Meaningful Clinical Use June 5, 2017

ASCO 2017: Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275 June 5, 2017

Page 486 of 619